CASE COMMENTS: UNILATERAL PRACTICES - ABUSE OF DOMINANT POSITION - DENIGRATION - PREDATORY PRICING - PHARMACEUTICAL SECTOR

Predatory pricing: The French Competition Authority rejects the request for interim measures in a predatory pricing case in the pharmaceutical sector but continues its investigations on the merits of the case (Janssen-Cilag France)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. Aut. conc. dec. no. 09-D-28 of 31 July 2009 relating to practices of Janssen-Cilag France in the pharmaceutical sector The Commission's sector inquiry, which is still very much in the public eye, ended with the publication of a report on 8 July (Final Report of the Commission available on its website and see also the Commission Communication, Summary of the Pharmaceutical Sector Inquiry Report and the press release of 8 July 2009 No IP/09/1098) detailing a series of practices observed in the pharmaceutical sector which have yet to be classified under competition law. This will be the task of the Commission and the national competition authorities, before

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Anne Wachsmann, Nicolas Zacharie, Predatory pricing: The French Competition Authority rejects the request for interim measures in a predatory pricing case in the pharmaceutical sector but continues its investigations on the merits of the case (Janssen-Cilag France), 31 July 2009, Concurrences N° 4-2009, Art. N° 29270, pp. 117-119

Visites 2037

All reviews